Cure8 trial brief
Patients with ulcerative colitis and their clinicians may be interested because the study tests whether adding pentoxifylline to standard mesalamine improves disease activity measured by the Mayo Score over 6 months.
Adult patients with mild-to-moderate ulcerative colitis (not on steroids, immunosuppressants, or biologics), gastroenterologists, and IBD researchers interested in adjunctive anti-inflammatory therapies.
This is a Phase 2 randomized interventional trial (completed) testing pentoxifylline 400 mg twice daily as an add-on to standard mesalamine therapy (1 g three times daily) versus mesalamine alone in adults with ulcerative colitis. The registered primary outcome is change in the Mayo Score over 6 months.
Key eligibility excludes patients on systemic or rectal steroids, immunosuppressives, or biologics and excludes severe UC and colorectal cancer. The record reports planned enrollment of 60 participants and lists the study site at Mansoura University (Egypt).
The trial frames pentoxifylline as a methylxanthine derivative with antioxidant and anti-inflammatory properties and positions it as adjunctive therapy to potentially improve Mayo Score measures (rectal bleeding, stool frequency, endoscopy, physician assessment).
No efficacy results are reported in this registry entry; it is a trial record describing design, interventions, outcomes, and eligibility rather than study findings.
This entry is a clinicaltrials.gov record (Phase 2, completed) describing the study design and planned outcomes; no results are provided in the supplied text. The trial excluded patients on systemic steroids, immunosuppressants, or biologic therapies, so findings would apply mainly to patients eligible under these criteria.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
A new oral investigational drug (HRS-7085) is entering early human testing for moderate-to-severe ulcerative colitis. People with UC who have not benefited from approved therapies may be interested in trial options and...
This trial is testing a new experimental oral therapy (BRS201) aimed at reducing hydrogen sulfide–related metabolites in people with mild ulcerative colitis. If successful, the drug could represent a novel, non-biologic...
Pediatric-onset IBD can behave differently than adult-onset disease. Comparing conventional versus biologic approaches in children may help clarify relative effectiveness, safety, and impacts on growth and steroid...
